Prevalence of cardiometabolic co-morbidities in patients with vs persons without chronic hepatitis B: The FitLiver cohort study  

作　　者：Sofie Jespersen Asmita Fritt-Rasmussen Sten Madsbad Bente K Pedersen Rikke Krogh-Madsen Nina Weis 

机构地区：[1]Department of Infectious Diseases,Copenhagen University Hospital,Hvidovre,Denmark [2]Centre for Physical Activity Research,Copenhagen University Hospital,Rigshospitalet,Denmark [3]Department of Endocrinology,Copenhagen University Hospital,Hvidovre,Denmark

出　　处：《World Journal of Hepatology》2025年第1期73-85,共13页世界肝病学杂志(英文)

基　　金：Supported by The Centre for Physical Activity Research(CFAS),TrygFonden,No.125132;and The Beckett Foundation,No.22-2-9924.

摘　　要：BACKGROUND Chronic hepatitis B(CHB)affects>300 million people worldwide.The combi-nation of CHB and cardiometabolic co-morbidities increases the risk of liver-related morbidity and mortality.However,international guidelines for CHB treatment do not provide recommendations for follow-up examinations or treatment of patients with CHB and cardiometabolic comorbidities.In studies investigating cardiometabolic co-morbidity in patients with CHB,inconsistent findings have been observed,and both lower and higher prevalence of car-diometabolic co-morbidities compared to the general population have been re-ported.It is unclear whether patients with CHB living in Denmark have an increased prevalence of cardiometabolic co-morbidities.We examined patients with CHB and age-,sex-,body mass index(BMI)-,and country-of-birth matched comparison group.Defining cardiometabolic co-morbidity:Obesity(BMI>25 kg/m2/abnormal waist-to-hip ratio),metabolic dysfunction-associated steatotic liver disease(MASLD),hypercholesterolemia(total-cholesterol>5 mmol/L/statin use),hypertension(systolic≥135 mmHg/diastolic≥85 mmHg/antihypertensive medication)and type 2 diabetes(T2D)(2-hour oral glucose tolerance test glucose>11.1 mmol/L/HbA1c>48 mmol/mol/antidiabetic medication).Physical activity was evaluated using maximal oxygen consumption(VO2max),activity monitors,and a questionnaire.RESULTS We included 98 patients with CHB and 49 persons in the comparison group.The two groups were well-matched,showing no significant differences in age,sex,BMI,country-of-birth,education,or employment.Among patients with CHB,the following prevalence of cardiometabolic co-morbidity was found:77%were obese,45%had MASLD,38%had hypercholesterolemia,26%had hypertension,and 7%had T2D,which did not differ significantly from the comparison group,apart from lower prevalence of hemoglobin A1c(HbA1c)≥48 mmol/L or known T2D.Both groups had low VO2max of 27 mL/kg/minute in the patients with CHB and 30 mL/kg/minute in the comparison group,and the patients with CHB had a shorter

关 键 词：Viral hepatitis B Diabetes Metabolic dysfunction-associated steatotic liver disease Hypertension HYPERCHOLESTEROLEMIA Obesity Physical activity 

分 类 号：R51[医药卫生—内科学]